not tagged
eli lilly
['leusm', 'lymsm', 'loxo']
at #eha2023, results from a first-in-human phase 1 study of an orally available selective bcl2 inhibitor, in patients with advanced hematologic malignancies. #leusm #lymsm learn more here: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK